Country: Malta
Language: English
Source: Medicines Authority
IBUPROFEN, PSEUDOEPHEDRINE HYDROCHLORIDE
Reckitt Benckiser Healthcare International Limited Thane Road, Nottingham NG90 2DB, United Kingdom
M01BX
IBUPROFEN, PSEUDOEPHEDRINE HYDROCHLORIDE
COATED TABLET
IBUPROFEN 200 milligram(s) ; PSEUDOEPHEDRINE HYDROCHLORIDE 30 milligram(s)
OTC
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
Authorised
2006-02-28
Reckitt Benckiser 0025 375 article 31 ibup 1.3.1 Package Leaflet Ibuprofen Pseudoephedrine HCl 200mg 30mg Tablets Page 1 Reckitt Benckiser 0025 375 article 31 ibup 1.3.1 Package Leaflet Ibuprofen Pseudoephedrine HCl 200mg 30mg Tablets Page 2 Read the complete document
Page 1 of 10 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Nurofen Cold & Flu Nurofen Sinus Relief 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredients Quantity Ibuprofen BP 200mg Pseudoephedrine Hydrochloride 30mg 3 PHARMACEUTICAL FORM Yellow film coated tablet. Printed in black with an identifying motif. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the relief of symptoms cold and 'flu with associated congestion, including aches and pains, headache, fever, sore throat, blocked nose and sinuses. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral administration and short-term use only. Adults, the elderly and children over 12 years: Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). The patient should consult a doctor if symptoms persist or worsen, or if the product is required for more than 10 days. Take 1 or 2 tablets with water, up to three times a day as required. Leave at least 4 hours between doses. Do not take more than 6 tablets in any 24 hour period. Page 2 of 10 Not to be given to children under 12 years. 4.3 CONTRAINDICATIONS Hypersensitivity to ibuprofen or any of the excipients in the product. Patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, angioedema, or urticaria) in response to aspirin or other non-steroidal anti-inflammatory drugs. Active or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding). History of gastrointestinal bleeding or perforation, related to previous NSAIDs therapy. Severe heart failure (NYHA Class IV), renal failure or hepatic failure (see section 4.4) Last trimester of pregnancy (see section 4.6) Patients with serious cardiovascular disease, tachycardia, hypertension, angina pectoris, hyperthyroidism, diabetes, phaeochromocytoma, closed angle glaucoma, prostatic enlargement. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Undesirable effects may be minimi Read the complete document